TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
出版年份 2014 全文链接
标题
TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
作者
关键词
-
出版物
MEDIATORS OF INFLAMMATION
Volume 2014, Issue -, Pages 1-7
出版商
Hindawi Limited
发表日期
2014-03-19
DOI
10.1155/2014/172821
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors
- (2013) A. C. Moss et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future
- (2013) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Targeting TNF-α for the treatment of inflammatory bowel disease
- (2013) Thomas Billiet et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis
- (2013) Omoniyi J. Adedokun et al. INFLAMMATORY BOWEL DISEASES
- Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease
- (2013) Hirotsugu Imaeda et al. JOURNAL OF GASTROENTEROLOGY
- TNFR2 Is Critical for the Stabilization of the CD4+Foxp3+ Regulatory T Cell Phenotype in the Inflammatory Environment
- (2013) X. Chen et al. JOURNAL OF IMMUNOLOGY
- Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cellsin vitrofrom Patients with Clinically Active Ulcerative Colitis
- (2013) R. Dahlén et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Letter: detection of infliximab levels and anti-infliximab antibodies - comparison of three different assays
- (2012) E. Parussini ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Letter: detection of infliximab levels and anti-infliximab antibodies - comparison of three different assays; authors’ reply
- (2012) D. J. Buurman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
- (2012) N. Vande Casteele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
- (2012) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
- (2012) Axel Dignass et al. Journal of Crohns & Colitis
- Paradoxical inflammation induced by anti-TNF agents in patients with IBD
- (2012) Isabelle Cleynen et al. Nature Reviews Gastroenterology & Hepatology
- Review article: infliximab for Crohn’s disease treatment - shifting therapeutic strategies after 10 years of clinical experience
- (2011) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease
- (2011) R. K. Russell et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: remission rates achievable by current therapies for inflammatory bowel disease
- (2011) L. Peyrin-Biroulet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Th17-related cytokines: new players in the control of chronic intestinal inflammation
- (2011) Ivan Monteleone et al. BMC Medicine
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity
- (2011) Xin Chen et al. FEBS LETTERS
- Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease
- (2011) Benjamin Pariente et al. INFLAMMATORY BOWEL DISEASES
- Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohnʼs Disease
- (2011) Toshifumi Hibi et al. INFLAMMATORY BOWEL DISEASES
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
- (2010) Jeffrey S Hyams et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
- (2010) S. Ben-Horin et al. GUT
- Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents
- (2010) Stephen B. Hanauer et al. INFLAMMATORY BOWEL DISEASES
- Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics
- (2010) William J. Sandborn et al. INFLAMMATORY BOWEL DISEASES
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
- (2009) Adedigbo A. Fasanmade et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
- (2009) Andrea Cassinotti et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
- (2008) F Schnitzler et al. GUT
- Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
- (2008) Zhenhua Xu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
- (2007) Mark A. Ainsworth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started